Cryopreservation of Cells Patents: Top Companies & Trends 2026
Cryopreservation and Formulation of Cells: Patents Shaping Post-Thaw Viability
Filings peaked in 2022 at 52 and dropped roughly 70% between 2021 (44) and 2024 (13), the last year with a complete publication record. Filings ran from 49 in 2017 to a peak of 52 in 2022, then fell to 13 by 2024 — a decline of about 70% across the 2021-2024 span. The 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a continuing drop.
- 1TAKEDA PHARMA CO LTD57
- 2SHIRE HUMAN GENETIC THERAPIES INC49
- 3INSTIL BIO UK LTD40
- 4MICROVASCULAR TISSUES INC38
- 5JANSSEN PHARMA NV27
See the full cryopreservation and formulation of cells analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on cryopreservation patents
Who holds the most patents in cell cryopreservation and formulation?
The dataset ranks 100 assignees, and the leader holds 57 of the 682 records in scope, well ahead of the fifth-place assignee at 27 and the tenth-place assignee at 20. The top five combined account for 30.9% of all records, and the top ten for 46.8%, which means over half the field is spread thinly across the remaining 90 ranked entities. This concentration pattern is typical of a field with a few large pharmaceutical and biotech filers alongside many smaller or single-filing entrants.
Is patent filing in cell cryopreservation still growing?
Filing activity peaked in 2022 at 52 records and had fallen to 13 by 2024, a roughly 70% decline over that three-year span using only complete-year data. The 2025 and 2026 figures are not yet reliable because publication typically lags filing by about 18 months, so recent applications are still working through the pipeline. Treat the 2021-2024 decline as the current signal rather than assuming the trend continues into the present year.
What is the difference between DMSO-based and DMSO-free cryopreservation patents in this landscape?
Most representative filings in this dataset, including the featured BOE Regenerative Medicine filing, use dimethyl sulfoxide as the core cryoprotectant alongside buffered salts and a sugar source such as glucose. DMSO-free formulation appears in the search scope but shows comparatively thinner direct coverage, making it one of the areas flagged as under-claimed relative to the dominant DMSO-based approach. Anyone evaluating a DMSO-free formulation should check this branch specifically rather than assuming the same density of prior art as the DMSO-based core.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Cryopreservation and Formulation of Cells covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.